

Non-Small Cell Lung Cancer: Update Bulletin [Jan 2016]

<https://marketpublishers.com/r/N4FB25977C6EN.html>

Date: December 2015

Pages: 0

Price: US\$ 995.00 (Single User License)

ID: N4FB25977C6EN

Abstracts

Gain new KOL insights on the latest events that have the potential to shape the targeted treatment of Non-Small Cell Lung Cancer (NSCLC). Topics covered include opinions about Tagrisso (osimertinib; AstraZeneca) as a newly approved second-line treatment for EGFR T790M mutation-positive NSCLC, the approval of Portrazza (necitumumab; Eli Lilly) for first-line squamous NSCLC therapy, and the expansion of the label for Xalkori (crizotinib; Pfizer) to include the first-line treatment of patients in the EU with ALK-positive NSCLC and patients in the US with ROS1-positive advanced NSCLC. KOLs also discuss Alecensa (alectinib; Roche) following its approval as a second-line treatment for ALK-positive metastatic NSCLC, and assess topline KEYNOTE-010 trial data for Keytruda (pembrolizumab; Merck & Co.) in the second-line treatment of PD-L1 positive advanced NSCLC.

Key Questions Answered in this Update Bulletin:

Will the safety and efficacy of AstraZeneca's Tagrisso prove sufficient to position it as the second-line treatment of choice for EGFR T790M mutation-positive NSCLC?

Is the overall survival (OS) advantage shown by Eli Lilly's Portrazza over chemotherapy likely to justify its cost as a first-line therapy for squamous NSCLC?

If approved, how widespread is the use of Pfizer's Xalkori as a first-line treatment for ALK-positive advanced NSCLC, in the EU, likely to be?

As Xalkori awaits approval for the treatment of ROS1-positive metastatic

NSCLC in the US, how successful do KOLs think the agent will be in this setting?

Can the favourable toxicity profile and significant CNS activity of Roche's Alecensa help it to secure a role as standard treatment for second-line ALK-positive metastatic NSCLC?

To what extent will the OS advantage shown by topline KEYNOTE-010 data impact the use of Merck's Keytruda as a second-line treatment for PD-L1 positive advanced NSCLC?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

I would like to order

Product name: Non-Small Cell Lung Cancer: Update Bulletin [Jan 2016]

Product link: <https://marketpublishers.com/r/N4FB25977C6EN.html>

Price: US\$ 995.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N4FB25977C6EN.html>